Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated intravenous NK-104-NP in pulmonary arterial hypertension
jRCT2031180075Suspended
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2019
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label trial of NK-104-NP in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Japan Agency for Medical Research and Development. Started Jan 2019; status: suspended.
02
Drugs
NK-104-NP
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2031180075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031180075.